Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions

Solid Tumor

Interventions

DRUG

C019199

The C019199 will be taken orally, once a day

DRUG

Sintilimab

Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.

Trial Locations (2)

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Fujian Haixi Pharmaceuticals Co., Ltd.

INDUSTRY